Coley Pharmaceutical Group and GlaxoSmithKline Enter Into License Agreement For Development of Cancer Vaccines.-- Companies to Develop Vaccines Containing CpG Immunostimulants -- Coley coley Noun Brit an edible fish with white or grey flesh [perhaps from coalfish] Pharmaceutical Group and GlaxoSmithKline (LONDON; NYSE NYSE See: New York Stock Exchange : GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) ) announced today that the companies have entered into a license agreement for the development of prophylactic and therapeutic cancer vaccines combining Coley's CpG immunostimulatory oligonucleotides (oligos) and GlaxoSmithKline's cancer antigens. The agreement, the second GSK-Coley license agreement, provides GSK with a worldwide non-exclusive license to Coley's proprietary CpG immunostimulatory oligos for use as adjuvants in cancer vaccines. In exchange, Coley has received $4 MM in license issue fees and upon the achievement of certain milestones, will receive future payments, as well as license maintenance fees and royalties on products developed through the collaboration. Should cancer vaccines be successfully developed and marketed, Coley will also receive royalties on net sales Net Sales The amount a seller receives from the buyer after costs associated with the sale are deducted. Notes: This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight of vaccines. "We believe that Coley's CpG oligonucleotide immunostimulants will provide a significant enhancement to vaccine-induced immune responses required to treat these difficult cancers," said Jean Stephenne, President and General Manager, GlaxoSmithKline Biologicals. "We are pleased to expand the scope of our existing relationship with Coley in infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. vaccines development to include the development of our anti-cancer "Pharmacine" vaccines." "I am delighted that GSK has made CpGs an essential ingredient in their strategy to develop anti-cancer vaccines," said Robert L. Bratzler, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Coley Pharmaceutical Group. "GSK is a world leader in vaccine development, and this agreement provides another validation of the potential clinical utility of our vaccine adjuvants." About GlaxoSmithKline GlaxoSmithKline Biologicals, the world's leading vaccine manufacturer, is located in Rixensart, Belgium. Rixensart is the centre of all GlaxoSmithKline's activities in the field of vaccine research, development and production. GSK Biologicals employs over 1,000 research scientists who are devoted to discovering new vaccines and developing more cost-effective and convenient combination products to prevent infections, which cause serious medical problems worldwide. In the year 2001 GSK Biologicals distributed over 900 million doses of vaccines to 171 countries, an average of 29 doses per second. GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer About Coley Pharmaceutical Group Coley Pharmaceutical Group is developing several classes of immunomodulatory oligonucleotide drugs with broad potential applications in cancer, asthma, allergy and infectious diseases. The current CpG drug candidates activate the human immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. to fight disease. Coley has 16 Phase I and Phase II clinical trials completed or ongoing with its lead product candidate, CpG 7909, a B-Class oligo. CpG 7909 is being evaluated in clinical trials as a monotherapy for melanoma and renal cell carcinoma renal cell carcinoma or hypernephroma Malignant tumour of the cells that cover and line the kidney. It usually affects persons over age 50 who have vascular disorders of the kidneys. It seldom causes pain, unless it is advanced. , and in combination with Rituxan(R) (Mabthera(R)) for non-Hodgkin's B-cell lymphoma and with Herceptin(R) for breast cancer. Coley has established a novel Human Cell Screening drug discovery and development platform for the rapid validation and optimization of new product candidates. Coley has product development and licensing agreements with Aventis Pharmaceuticals, Inc. for the development of CpG 7279 and other products for the treatment of asthma and allergic rhinitis Allergic Rhinitis Definition Allergic rhinitis, more commonly referred to as hay fever, is an inflammation of the nasal passages caused by allergic reaction to airborne substances. , as well as a licensing agreements with GlaxoSmithKline for the use of certain CpG drug candidates in specified preventive and therapeutic infectious disease vaccines, and cancer vaccines. Coley's patent portfolio includes 65 U.S. patents and patent applications and their worldwide counterparts, including ten U.S. patents that have been issued. Coley is a private company with operations in the United States, Germany and Canada. For further information, please visit http://www.coleypharma.com/. Herceptin(R) is a registered trademark of Genentech, Inc. Rituxan(R) is a registered trademark of IDEC Pharmaceuticals. Mabthera(R) is a registered trademark of F. Hoffman-LaRoche. Contact: Patricia F. Dimond, Ph.D. VP, Corporate Communications Strategic Development Coley Pharmaceutical Group +1.781.431.9000 x1257 pdimond@coleypharma.com Karla MacDonald or Shannon Altimari Feinstein Kean Healthcare (U.S.) +1.617.577.8110 kmacdonald@fkhealth.com saltimari@fkhealth.com Michael Sinclair Burns McClellan (Europe) +44.20.7534.1520 msinclair@burnsmc.co.uk Make Your Opinion Count - Click Here http://tbutton.prnewswire.com/prn/11690X06552755 CONTACT: Patricia F. Dimond, Ph.D., VP, Corporate Communications Strategic Development of Coley Pharmaceutical Group, +1-781-431-9000 ext. 1257, pdimond@coleypharma.com; or Karla MacDonald, kmacdonald@fkhealth.com, or Shannon Altimari, saltimari@fkhealth.com, of Feinstein Kean Healthcare (U.S.), +1-617-577-8110; or Michael Sinclair of Burns McClellan (Europe), +44.20.7534.1520, msinclair@burnsmc.co.uk Web site: http://www.coleypharma.com/ |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion